The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a pilot program for the Rare Therapies Launch Pad, an initiative aimed at streamlining regulatory pathways for individualized medicines. The program, led by Julia Vitarello and biotech company EveryONE Medicines, will test a ‘Process to Product’ approach, where regulators approve standardized manufacturing processes rather than individual treatments. This follows the first treatment under a Master Protocol trial in January 2026, marking progress toward enabling faster access to personalized therapies for rare genetic diseases. The MHRA’s shift reflects growing recognition of the need to adapt regulatory systems to emerging gene and cell therapies, though challenges remain in scaling access for millions with rare conditions.
© Crown copyright, 2024, GOV.UK.
Summary adapted from content licensed under the Open Government Licence v3.0.
For details, see https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/.
Original source: https://www.gov.uk/
https://www.gov.uk/government/news/mila-to-millions-a-new-era-of-individualized-medicines
Made by AI. If you spot anything of concern write us at contact@cybach.com. We’ll promptly correct irregularities.